The Pro Medicus Ltd (ASX: PME) share price is in focus after the company announced a binding Heads of Agreement with Echo IQ for a finance facility and reseller agreement, aiming to expand its AI-driven cardiology solutions.
Image source: Getty Images
What did Pro Medicus report?
- Signed a binding Heads of Agreement with Echo IQ Ltd for a financing arrangement
- Agreement includes a reseller arrangement for Echo IQ's AI algorithms in cardiology
- Focus on commercialising solutions for aortic stenosis and heart failure detection
- Definitive agreements expected within 20 business days or the transaction may lapse
What else do investors need to know?
Pro Medicus is broadening its AI strategy by adding third-party algorithms to its Visage 7 Cardiology platform, alongside in-house and partner-developed solutions. The finance facility for Echo IQ is designed to help accelerate its AI offerings, particularly in key disease areas.
While the Heads of Agreement sets out the framework, the deal is subject to final legal agreements. Pro Medicus has committed to updating shareholders once these are completed or if negotiations end without a deal.
What did Pro Medicus management say?
Chief Executive Officer Dr Sam Hupert said:
In addition to providing financial backing, we are looking to offer our Visage 7 Cardiology customers the option of Echo IQ's technology. This is in line with our AI strategy of offering a curated suite of algorithms that will be a mixture of algorithms created by us, those created in conjunction with our clinical partners and 3rd party algorithms such as Echo-IQ.
What's next for Pro Medicus?
Pro Medicus plans to proceed with negotiating definitive agreements with Echo IQ over the next 20 business days. The move supports its ambition to grow market offerings and provide innovative, AI-powered cardiology solutions to its customers.
If successful, the agreement will further expand Pro Medicus' AI capabilities and commercial reach, reinforcing its growth strategy in health imaging.
Pro Medicus share price snapshot
Over the past 12 months, Pro Medicus shares have declined 35%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.
